The UK’s Prescription Medicines Code of Practice Authority (PMCPA) issued its final resolution in a 2025 case following a voluntary admission by Pfizer, concluding that the company failed to maintain high standards, certify required materials, and ensure appropriate hospitality.
The PMCPA case identifies multiple breaches of the Association of
Register for free to keep reading
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day